Archive: March 2017

The Use of Immunotherapy in the First-Line Treatment of Lung Cancer

Naiyer A. Rizvi, MD

  H&O  How does immunotherapy in lung cancer work? NR  There has been tremendous recent progress in the understanding of how immunotherapy works in lung cancer. […]

The New NCCN Guidelines for the Management of Myelofibrosis

Ruben A. Mesa, MD

H&O  What is myelofibrosis? RM  Myelofibrosis is a myeloproliferative neoplasm, a type of chronic leukemia. Myelofibrosis can evolve from an antecedent polycythemia vera or essential thrombocythemia, […]

Natural Killer/T-Cell Lymphomas in Pediatric and Adolescent Patients

Amanda M. Termuhlen, MD

  Abstract: Natural killer/T-cell (NK/T-cell) lymphomas are rare in children and adolescents and consist predominantly of nasal-type extranodal NK/T-cell lymphomas. More than half of pediatric/adolescent patients […]

BCL-2 As a Therapeutic Target in Chronic Lymphocytic Leukemia

Catherine Daniel, MD, and Anthony R. Mato, MD, MSCE

  Abstract: Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) […]

Prognostic and Predictive Biomarkers in Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM

  H&O  What are biomarkers in the context of metastatic castration-resistant prostate cancer (mCRPC)? AJA  Biomarkers are any manifestation of a biological process, particularly in patients, […]

Prevention and Management of Thrombosis in Myeloproliferative Neoplasms

Mallika Sekhar, MBBS, MD, FRCP, FRCPath

H&O  What are the various myeloproliferative neoplasms (MPNs)? MK  The conventional BCR-ABL–negative MPN cat­egories are polycythemia vera (PV), essential throm­bocythemia (ET), myelofibrosis, unclassified MPN (MPN-U), chronic […]

The Evolving Role of Cyclin-Dependent Kinase Inhibitors in Cancer Management

Geoffrey I. Shapiro, MD, PhD

  H&O  What is the role of cyclin-dependent kinases, and why are they a target in cancer treatment? GS  The cyclin-dependent kinases (CDKs) are a large […]

Letter From the Editor: When Will We Beat R-CHOP?

Brad S. Kahl, MD

I was joking around with one of my AML colleagues a while back, teasing him about giving 7 + 3 chemotherapy. That recipe has been around […]

Back to Archive